<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Corbus Pharmaceuticals Holding — News on 6ix</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding</link>
<description>Latest news and press releases for Corbus Pharmaceuticals Holding on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/corbus-pharmaceuticals-holding" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835591478dffbe2df0eae1c.webp</url>
<title>Corbus Pharmaceuticals Holding</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding</link>
</image>
<item>
<title>Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-abstracts-accepted-for-presentation-at-asco-2026-featuring-updated-clinical-data-for-crb-701</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-abstracts-accepted-for-presentation-at-asco-2026-featuring-updated-clinical-data-for-crb-701</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June</description>
</item>
<item>
<title>Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss</description>
</item>
<item>
<title>Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-to-participate-in-the-bmo-2026-metabolic-health-summit</guid>
<pubDate>Wed, 18 Mar 2026 12:00:00 GMT</pubDate>
<description>NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026. Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse</description>
</item>
<item>
<title>Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-q4-and-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-q4-and-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-present-36th-annual-130000531</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-present-36th-annual-130000531</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-present-44th-annual-123000833</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-present-44th-annual-123000833</guid>
<pubDate>Mon, 05 Jan 2026 12:30:00 GMT</pubDate>
<description>NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA. 44th Annual J.P. Morgan Healthcare Conference Format: Presentation and one-on-one investor meetings Date: January 15, 202</description>
</item>
<item>
<title>Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-results-phase-120000223</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-results-phase-120000223</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cor</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-report-results-phase-210100268</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-report-results-phase-210100268</guid>
<pubDate>Wed, 10 Dec 2025 21:01:00 GMT</pubDate>
<description>Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live</description>
</item>
<item>
<title>Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-third-quarter-130000140</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-third-quarter-130000140</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75 million public offering, extending cash runway into 2028Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025 NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”),</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-participate-upcoming-investor-130000246</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-participate-upcoming-investor-130000246</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be participating in the following investor conferences. Guggenheim’s Second Annual Healthcare Innovation Conference in BostonFormat: Presentation and one-on-one investor meetings Date: November 12, 2025 Presentation time: 1:00pm ET Webcast link: Click here Jefferies Global Healthcare Conference in LondonFormat</description>
</item>
<item>
<title>Corbus Pharmaceuticals Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-pricing-public-064000852</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-pricing-public-064000852</guid>
<pubDate>Fri, 31 Oct 2025 06:40:00 GMT</pubDate>
<description>NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant,</description>
</item>
<item>
<title>Corbus Pharmaceuticals Announces Proposed Public Offering</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-proposed-public-203100532</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-proposed-public-203100532</guid>
<pubDate>Thu, 30 Oct 2025 20:31:00 GMT</pubDate>
<description>NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market condit</description>
</item>
<item>
<title>Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-presents-crb-701-070000246</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-presents-crb-701-070000246</guid>
<pubDate>Sat, 18 Oct 2025 07:00:00 GMT</pubDate>
<description>3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSCC KOL event during ESMO25 NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poste</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-present-crb-701-120000269</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-present-crb-701-120000269</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 abstract for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster durin</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-participate-upcoming-piper-120000782</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-participate-upcoming-piper-120000782</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium, to be held October 9-10, 2025. Piper Sandler clients can register for the event through their representative. Corbus Fireside ChatOctober 9, 2025, 10:00AM ETHos</description>
</item>
<item>
<title>Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-host-person-virtual-120000464</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-host-person-virtual-120000464</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that it will host an in-person and virtual KOL event at the European Society for Medical Oncology (ESMO) Congress 2025 to review and discuss dose optimization data from its Phase 1/2 clinical study of CRB-701 (SYS6002). Data from</description>
</item>
<item>
<title>FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/fda-grants-fast-track-designation-120000929</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/fda-grants-fast-track-designation-120000929</guid>
<pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
<description>Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamo</description>
</item>
<item>
<title>Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-second-quarter-120000587</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-reports-second-quarter-120000587</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025 NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported fi</description>
</item>
<item>
<title>Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress</title>
<link>https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-upcoming-presentation-120000043</link>
<guid isPermaLink="true">https://6ix.com/company/corbus-pharmaceuticals-holding/news/corbus-pharmaceuticals-announces-upcoming-presentation-120000043</guid>
<pubDate>Wed, 30 Jul 2025 12:00:00 GMT</pubDate>
<description>NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the United States and Europe of CRB-701 (SYS6002) has been accepted for presentation as a poster at the European Society for Medical Oncology (ESMO) Congress 2025, to be held October 17-21, 2025 in Berlin, Germany. The abstract, a Pha</description>
</item>
</channel>
</rss>